Background 177Lu]Lu-prostate-specific membrane antigen (PSMA) is an effective treatment for metastatic castration-resistant prostate cancer (mCRPC). Currently, doctors use a special imaging scan (SPECT/CT) 24 hours after treatment to evaluate how well it’s working. However, this timing is inconvenient for patients.
Study Purpose The researchers wanted to see if they could get similar results by doing the scan just 4 hours after treatment instead of waiting 24 hours.
Methods 21 patients with advanced prostate cancer were included in the study. Patients received 177LuLu-PSMA-I&T treatment. Scans were done at 4 and 24 hours after the first dose, and 4 hours after the second dose. The researchers compared the results of the 4-hour and 24-hour scans.
Results The 4-hour and 24-hour scans showed similar overall results for most measurements. The 4-hour scan missed some very small tumors (less than 2 cm) that were visible on the 24-hour scan. Changes in total tumor volume between the first and second treatments, as seen on the 4-hour scans, could predict how long patients would remain free from cancer progression.
Conclusion The 4-hour scan appears to be a promising alternative to the 24-hour scan for assessing treatment response. This method would be more convenient for patients while still providing valuable information about the treatment’s effectiveness.
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)